D-Leucine amide-CDDO-Me-HMP

D-Leucine amide-CDDO-Me-HMP is a prodrug composed of CDDO-Me (HY-13324) and ligustrazine (HY-N0264) . D-Leucine amide-CDDO-Me-HMP can protect against CCl4-induced liver injury. D-Leucine amide-CDDO-Me-HMP can inhibit ROS production, alleviates mitochondrial damage and inhibits cell apoptosis. D-Leucine amide-CDDO-Me-HMP can be used for the research of liver injury[1].

Product Specifications

CAS Number

[2749600-16-4]

UNSPSC

12352005

Target

Apoptosis; Bcl-2 Family; Caspase; Drug Intermediate; Heme Oxygenase (HO) ; Keap1-Nrf2; Reactive Oxygen Species (ROS)

Related Pathways

Apoptosis; Immunology/Inflammation; Metabolic Enzyme/Protease; NF-κB; Others

Applications

Metabolism-protein/nucleotide metabolism

Field of Research

Metabolic Disease

Smiles

[H][C@@]12CC(C)(CC[C@@]1(CC[C@]3([C@@]4(CC[C@]5(C(C)(C(OCC6=CC=C(C=C6)NC([C@@H](CC(C)C)N)=O)=C(C([C@@]5(C4=CC([C@]23[H])=O)C)OCC7=NC(C)=C(N=C7C)C)C#N)C)[H])C)C)C(OC)=O)C

Molecular Formula

C53H73N5O6

Molecular Weight

876.18

References & Citations

[1]Chen F, et al. Development of a leucine aminopeptidase-activatable co-prodrug from CDDO-Me and ligustrazine for synergistic treatment of liver injury. Bioorg Chem. 2025;166:109177.